Therapies for dactylitis in psoriatic arthritis. A systematic review.
Dactylitis is a hallmark clinical feature of psoriatic arthritis (PsA). Acute dactylitis appears to be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory rheumatic drugs and local corticosteroid injections to treat dactylitis, although conventional disease modifying antirheumatic drugs also are recommended. In this systematic review, the limited data on treatments for dactylitis in PsA highlight the need for a valid, reliable, and responsive clinical outcome measure. Infliximab is the only drug to demonstrate significant improvement of dactylitis during a clinical study.
Helliwell
Philip S
PS
Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK. p.helliwell@leeds.ac.uk
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005938:Glucocorticoids / Q000627:therapeutic use*; D050823:Hand Joints / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D000069285:Infliximab; D007270:Injections, Intra-Articular; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D000069285:Infliximab